Merck and J&J settle Remicade battle – and investors' nerves
This article was originally published in Scrip
Executive Summary
Merck & Co has ended an arbitration dispute with Johnson & Johnson and pleased investors with news that, as part of a settlement, it would be holding onto a good chunk of its distribution rights to the TNF-inhibitor Remicade (infliximab).